Synta to Present at the Deutsche Bank 2012 dbAccess BioFEST

Synta to Present at the Deutsche Bank 2012 dbAccess BioFEST

<0> Synta Pharmaceuticals Corp.George Farmer, 781-541-7125 </0>

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3 at 10:45 a.m. (EST) in Boston.

A live audio and replay of the presentation will be available on the "Investors" section of the Company's website, .

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit .

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.